Therapeutic management of hyperprolactinemia: a literature review
DOI:
https://doi.org/10.33448/rsd-v10i15.22554Keywords:
Endocrinology; Hyperprolactinemia; Revision; Therapy.Abstract
Introduction: Prolactin (PRL) is a hormone synthesized and secreted by the lactotrophic cells of the anterior pituitary, whose main function is to stimulate lactation. Hyperprolactinemia is defined as excess production of prolactin and is the most common pituitary hormonal disorder found in medical practice. Methodology: It consists of a literature review, with a qualitative and integrative approach, on the therapeutic management of hyperprolactinemia. Scientific texts were selected from the Scientific Electronic Library Online (SciELO) and from the U.S. National Library of Medicine (PubMED), using the descriptors “hyperprolactinemia” and “treatment”. Results and discussion: The therapeutic management of hyperprolactinemia depends on establishing its etiology, which can be pathological, including prolactinomas and primary hypothyroidism; pharmacological, with the use of antipsychotics; or physiological, due to chest wall injuries, stress or breastfeeding. In general, treatment is aimed at preserving or restoring gonadal function and preventing side effects of increased PRL levels, such as osteoporosis. Conclusion: With the review of the scientific literature, it is clear that the investigation of the etiology of hyperprolactinemia is essential for the therapeutic decision. The classic approach, performed with AD, especially CAB, is still considered the first line for the treatment of prolactinomas, regardless of size. Other drug options include HRT, such as Tamoxifen and Clomiphene, which have been shown to be beneficial options for invasive and resistant macroprolactinomas; and restoration of eugonadism, respectively.
References
Aguirre, M. A., Luna, M., Reyes, Y., Zerpa, Y., & Vielma, M. (2013). Diagnóstico y manejo de la hiperprolactinemia. Revista Venezolana de Endocrinología y Metabolismo, 11(1), 26-38.
Auriemma, R. S., Pirchio, R., De Alcubierre, D., Pivonello, R., & Colao, A. (2019). Dopamine agonists: from the 1970s to today. Neuroendocrinology, 109(1), 34-41.
Botelho, L. L. R., de Almeida Cunha, C. C., & Macedo, M. (2011). O método da revisão integrativa nos estudos organizacionais. Gestão e sociedade, 5(11), 121-136.
Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Portaria nº 1.160, de 18 de novembro de 2015.
Casanueva, F. F., Molitch, M. E., Schlechte, J. A., Abs, R., Bonert, V., Bronstein, M. D., ... & Giustina, A. (2006). Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical endocrinology, 65(2), 265-273.
Chanson, P., & Maiter, D. (2019). The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best practice & research Clinical endocrinology & metabolism, 33(2), 101290.
Ciccarelli, A., Daly, A. F., & Beckers, A. (2005). The epidemiology of prolactinomas. Pituitary, 8(1), 3-6.
dos Santos Nunes, V., Vicentini, H. C., Padovani, C. R., Nogueira, C. R., & Vilar, L. (2017). Electronic survey of management of hyperprolactinemia in Brazil: Endocrinologists versus gynecologists. Revista Argentina de Endocrinología y Metabolismo, 54(3), 124-129.
Glezer, A., & Bronstein, M. D. (2014). Prolactinomas. Endocrinology and metabolism clinics of North America, 44(1), 71-78.
Kalinin, P. L., Astaf'eva, L. I., Kadashev, B. A., & Ismailov, D. B. (2017). Indications for surgical treatment of prolactin-secreting pituitary adenomas. Zhurnal voprosy neirokhirurgii imeni NN Burdenko, 81(5), 117-124.
Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. (2011). Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 96(2), 273-288.
Pekić, S., Stojanoska, M. M., & Popovic, V. (2019). Hyperprolactinemia/prolactinomas in the postmenopausal period: challenges in diagnosis and management. Neuroendocrinology, 109(1), 28-33.
Rosário, P. W., & Purisch, S. (2010). Acromegalia bioquímica em pacientes com prolactinoma em tratamento com agonistas dopaminérgicos. Arquivos Brasileiros de Endocrinologia & Metabologia, 54(6), 546-549.
Sadideen, H., & Swaminathan, R. (2006). Macroprolactin: what is it and what is its importance?. International journal of clinical practice, 60(4), 457-461.
Samperi, I., Lithgow, K., & Karavitaki, N. (2019). Hyperprolactinaemia. Journal of clinical medicine, 8(12), 2203.
Sickler, T. D. P. Análise da expressão da filamina A nos tumores hipofisários e suas implicações clínicas e terapêuticas (Doctoral dissertation, Universidade de São Paulo).
Tirosh, A., & Shimon, I. (2015). Current approach to treatments for prolactinomas. Minerva endocrinologica, 41(3), 316-323.
Vieira, J. G. H. (2002). Macroprolactinemia. Arquivos Brasileiros de Endocrinologia & Metabologia, 46, 45-50.
Vilar, L.; Naves, L. A. (2013) Avaliação diagnóstica da hiperprolactinemia. Endocrinologia Clínica. 5a ed. Rio de Janeiro: Guanabara Koogan, p. 39-49
Vilar, L., Abucham, J., Albuquerque, J. L., Araujo, L. A., Azevedo, M. F., Boguszewski, C. L., ... & Bronstein, M. D. (2018). Controversial issues in the management of hyperprolactinemia and prolactinomas–An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Archives of endocrinology and metabolism, 62, 236-263.
Wang, A. T., Mullan, R. J., Lane, M. A., Hazem, A., Prasad, C., Gathaiya, N. W., ... & Murad, M. H. (2012). Treatment of hyperprolactinemia: a systematic review and meta-analysis. Systematic reviews, 1(1), 1-12.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Bárbara Maria Paiva Corrêa; Rayana Queiroz da Silva; Victória Carollyne Bonfim Silva; Micaella Yanne Fender Lobato; Amanda de Paula; Manuela Salame Serique; Cristal Louise Antunes Gonçalves; Arthur Cesar Batista Rodrigues; Lorena Soriano de Melo Lima; João Marcos Rodrigues Silva; João Victor Castro Mota; Santino Carvalho Franco
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
